Cargando…

Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts

PURPOSE: To investigate whether black race is an independent predictor of overall survival (OS) in metastatic renal cell carcinoma (mRCC). METHODS: We performed a retrospective 2-cohort (International Metastatic Renal Cell Carcinoma Database Consortium [IMDC] and trial-database) study of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bossé, Dominick, Xie, Wanling, Lin, Xun, Simantov, Ronit, Lalani, Aly-Khan A., Graham, Jeffrey, Wells, J. Connor, Donskov, Frede, Rini, Brian, Beuselinck, Benoit, Alva, Ajjai, Hansen, Aaron, Wood, Lori, Soulières, Denis, Kollmannsberger, Christian, Patenaude, Francois, Heng, Daniel Y.C., Choueiri, Toni K., McKay, Rana R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055470/ https://www.ncbi.nlm.nih.gov/pubmed/32109159 http://dx.doi.org/10.1200/JGO.19.00380

Ejemplares similares

Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database
por: Fay, Andre P., et al.
Publicado: (2018)

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
por: Yip, Steven M., et al.
Publicado: (2017)

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
por: Lalani, Aly-Khan A., et al.
Publicado: (2022)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System
por: Cardenas, Luisa M., et al.
Publicado: (2023)

Pan-urologic cancer genomic subtypes that transcend tissue of origin
por: Chen, Fengju, et al.
Publicado: (2017)

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
por: Lalani, Aly-Khan A., et al.
Publicado: (2018)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2018)

Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
por: Donskov, Frede
Publicado: (2021)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
por: de Velasco, Guillermo, et al.
Publicado: (2018)

Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician
por: Storbjerg, Bent, et al.
Publicado: (2018)

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
por: Nguyen, Eric K., et al.
Publicado: (2022)

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma
por: Parmar, Ambica, et al.
Publicado: (2022)

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
por: Navani, Vishal, et al.
Publicado: (2022)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
por: Nguyen, Charles B., et al.
Publicado: (2022)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
por: Delea, T E, et al.
Publicado: (2012)

In Reply
por: de Velasco, Guillermo, et al.
Publicado: (2017)

Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia
por: Alva, Ajjai, et al.
Publicado: (2015)

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
por: Martinez Chanza, Nieves, et al.
Publicado: (2020)

The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer
por: Rubinstein, Samuel M., et al.
Publicado: (2020)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
por: Dudani, Shaan, et al.
Publicado: (2021)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
por: Marmarelis, Melina E., et al.
Publicado: (2016)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
por: Ghatalia, P, et al.
Publicado: (2015)

COVID-19 and Cancer: Current Challenges and Perspectives
por: Bakouny, Ziad, et al.
Publicado: (2020)

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
por: Bilen, Mehmet A., et al.
Publicado: (2022)

Abstract 6 Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Access and Outcomes for Patients with Hematologic Malignancies in the U.S.
por: Gergis, Usama, et al.
Publicado: (2022)

Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis
por: Shen, Meixiao, et al.
Publicado: (2014)

Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma()
por: Drljevic-Nielsen, Aska, et al.
Publicado: (2020)

Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
por: Drljevic-Nielsen, Aska, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f8i1q30jfvecjsjbfa4j6k5aqt